Suppr超能文献

在非透析慢性肾脏病患者中,心肌肌钙蛋白I浓度通常会升高:一项采用灵敏检测法的研究经验

Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay.

作者信息

Lamb Edmund J, Kenny Claire, Abbas Nasir A, John R Ian, Webb Michelle C, Price Christopher P, Vickery Susan

机构信息

Clinical Biochemistry, East Kent Hospitals NHS Trust, Canterbury, Kent.

出版信息

Am J Kidney Dis. 2007 Apr;49(4):507-16. doi: 10.1053/j.ajkd.2007.01.015.

Abstract

BACKGROUND

Cardiac troponin (cTn) concentrations commonly are increased in patients with chronic kidney disease (CKD) in the absence of an acute coronary syndrome. cTn T (cTnT) concentration reportedly is increased more commonly than cTn I (cTnI). Using a sensitive cTnI assay, we studied cTnI concentrations in predialysis patients with CKD who did not have an acute coronary event.

STUDY DESIGN

Observational cohort study.

SETTING AND PARTICIPANTS

Nondialysis patients with CKD attending an outpatient clinic.

PREDICTOR

Plasma cTnI was measured using the cTnI-Ultra assay (Bayer HealthCare LLC, Diagnostics Division, Tarrytown, NY), the same manufacturer's standard cTnI assay, and a cTnT assay (Roche Diagnostics PLC, East Sussex, UK).

OUTCOMES AND MEASUREMENTS

Prevalence of increased cTn concentration, effect of clinical variables on cTnI-Ultra concentration, and independent associations between cTn assays and all-cause mortality by using multiple regression modeling.

RESULTS

Plasma cTnI-Ultra concentration exceeded the upper limit of normal in 33% of patients compared with 18% with the cTnI-standard assay and 43% with the cTnT assay. Age, vascular disease, parathyroid hormone concentration, and left ventricular mass, but not kidney function, had independent effects on plasma cTnI-Ultra concentrations. There were 39 deaths during follow-up. Survival was decreased in patients with baseline cTnI-Ultra concentrations of 0.040 ng/mL or greater (54% versus 83%; P < 0.001), cTnI-standard concentrations of 0.07 ng/mL or greater (55% versus 78%; P = 0.02), and cTnT concentrations of 0.01 ng/mL or greater (59% versus 89%; P < 0.001). Only cTnT concentration was an independent predictor of death.

LIMITATION

Only all-cause mortality was recorded.

CONCLUSION

Using a sensitive assay, we found that the prevalence of increased cTnI concentrations in patients with CKD is similar to that observed for cTnT. cTnT concentration, but not cTnI, was independently associated with death.

摘要

背景

在没有急性冠状动脉综合征的慢性肾脏病(CKD)患者中,心肌肌钙蛋白(cTn)浓度通常会升高。据报道,肌钙蛋白T(cTnT)浓度升高比肌钙蛋白I(cTnI)更为常见。我们使用一种敏感的cTnI检测方法,研究了未发生急性冠状动脉事件的CKD透析前患者的cTnI浓度。

研究设计

观察性队列研究。

研究地点和参与者

在门诊就诊的非透析CKD患者。

预测指标

使用cTnI-Ultra检测法(拜耳医疗保健有限责任公司诊断部,纽约塔里敦)、同一厂家的标准cTnI检测法和cTnT检测法(罗氏诊断公司,英国东萨塞克斯)检测血浆cTnI。

结果和测量指标

通过多元回归模型分析cTn浓度升高的患病率、临床变量对cTnI-Ultra浓度的影响以及cTn检测法与全因死亡率之间的独立关联。

结果

33%的患者血浆cTnI-Ultra浓度超过正常上限,相比之下,cTnI标准检测法为18%,cTnT检测法为43%。年龄、血管疾病、甲状旁腺激素浓度和左心室质量对血浆cTnI-Ultra浓度有独立影响,但肾功能无此影响。随访期间有39例死亡。基线cTnI-Ultra浓度≥0.040 ng/mL的患者生存率降低(54%对83%;P<0.001),cTnI标准浓度≥0.07 ng/mL的患者生存率降低(55%对78%;P=0.02),cTnT浓度≥0.01 ng/mL的患者生存率降低(59%对89%;P<0.0(此处原文有误,应为P<0.001))。只有cTnT浓度是死亡的独立预测因素。

局限性

仅记录了全因死亡率。

结论

使用敏感检测法,我们发现CKD患者中cTnI浓度升高的患病率与cTnT相似。cTnT浓度而非cTnI浓度与死亡独立相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验